Category: Gilead
-
Gilead Sciences stock upgraded by Raymond James on strong growth outlook for new drugs By Investing.com
•
On Monday, Raymond James changed its stance on Gilead Sciences Inc. (NASDAQ:GIL) stock, upgrading it from “market perform” to “outperform.” The firm also set a $93.00 price target for the biopharmaceutical company. This update is bolstered by promising data from the PURPOSE-1 study of lenacapavir, a long-acting HIV pre-exposure prophylaxis…